




The relative strengths and weaknesses of Akari Therapeutics Plc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Akari Therapeutics Plc compared to the market average is the variable Other Assets, increasing the Economic Capital Ratio by 123% points. The greatest weakness of Akari Therapeutics Plc is the variable Assets, Current, reducing the Economic Capital Ratio by 43% points.

The company's Economic Capital Ratio, given in the ranking table, is 255%, being 25% points above the market average of 229%.

Input Variable	Value in 1000 USD
Assets, Current	5,462
Cost of Goods Sold	0
Intangible Assets	8,430
Liabilities, Current	12,351
Liabilities, Non-Current	31
Other Assets	34,000
Other Compr. Net Income	-44
Other Expenses	4,177
Other Liabilities	7,182
Other Net Income	-1,026
Other Revenues	0
Property and Equipment	0
Research and Development	2,815
Selling, General and Administrative Expense	9,280

Output Variable	Value in 1000 USD
Assets	47,892
Liabilities	19,564
Expenses	16,272
Revenues	0
Stockholders Equity	28,328
Net Income	-17,298
Comprehensive Net Income	-17,320
BaseVar	42,399
ECR before LimitedLiability	132%
Economic Capital Ratio	255%